Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase (ALK) fusion gene: A Single Technology Appraisal.

Ana Isabel Duarte; Jane Alison Burch; Alison Smith; Simon Mark Walker; Dave Fox; Rocio Rodriguez-Lopez; Stephen John Palmer; Alison Jane Eastwood

Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase (ALK) fusion gene: A Single Technology Appraisal.

Ana Isabel Duarte, Jane Alison Burch, Alison Smith, Simon Mark Walker, Dave Fox, Rocio Rodriguez-Lopez, Stephen John Palmer, Alison Jane Eastwood

Research output: Book/Report › Commissioned report

Original language	English
Publisher	NICE
Publication status	Published - 2013

Cite this

@book{113f3c3efb0847478332c37a2d65ccf1,

title = "Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase (ALK) fusion gene: A Single Technology Appraisal.",

author = "Duarte, {Ana Isabel} and Burch, {Jane Alison} and Alison Smith and Walker, {Simon Mark} and Dave Fox and Rocio Rodriguez-Lopez and Palmer, {Stephen John} and Eastwood, {Alison Jane}",

year = "2013",

language = "English",

publisher = "NICE",

}

TY - BOOK

T1 - Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase (ALK) fusion gene: A Single Technology Appraisal.

AU - Duarte, Ana Isabel

AU - Burch, Jane Alison

AU - Smith, Alison

AU - Walker, Simon Mark

AU - Fox, Dave

AU - Rodriguez-Lopez, Rocio

AU - Palmer, Stephen John

AU - Eastwood, Alison Jane

PY - 2013

Y1 - 2013

M3 - Commissioned report

BT - Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase (ALK) fusion gene: A Single Technology Appraisal.

PB - NICE

ER -